IS THE SYNTAX SCORE SUFFICIENT TO ASSESS THE RISK FOR PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS?
https://doi.org/10.21518/2307-1109-2017-1-80-93
Abstract
The article presents a comparative evaluation of the current clinical angiographic scales in the risk stratification for patients with stable coronary artery disease undergoing elective percutaneous coronary interventions. The article discusses the prospects for improving the prognostic value of scales by adding two laboratory markers reflecting the degree of coagulation cascade activation and the adequacy of antiplatelet therapy — D-dimer and residual platelet reactivity to adenosine diphosphate.
About the Authors
E. S. Novikova
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
Russian Federation
A. L. Komarov
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
Russian Federation
MD
E. V. Gus’kova
National Medical and Surgical Centre named after N.I. Pirogov, MoH RF
Russian Federation
Russian Federation
PhD in medicine
O. O. Shakhmatova
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
A. D. Deyev
National Research Center for Preventive Medicine, MoH RF
Russian Federation
Russian Federation
Mathematics Physics Ph.D.
A. B. Dobrovolsky
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
Russian Federation
D.Sc. (Biology), Prof.
A. N. Samko
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
Russian Federation
MD, Prof.
E. P. Panchenko
Russian Cardiology Research and Production Complex, MoH RF
Russian Federation
Russian Federation
MD, Prof.
References
1. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet, 2013, 381(9867): 629-638.
2. http: //www.syntaxscore.com/.
3. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg, 1999, 16(1): 9-13.
4. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923-1932.
5. Byrne A, Serruys PW, Baumbach A et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J, 2015 Oct 7, 36(38): 2608-20.
6. 2014 ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014 Oct 1, 35(37): 2541-619.
7. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал, 2015, 3(119): 35-42.
8. Комаров А.Л., Илющенко Т.А., Шахматова О.О., Деев А.Д., Самко А.Н., Панченко Е.П. Сравнительная эффективность консервативного и инвазивного лечения больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология, 2012, 52(8): 4-14.
9. Serruys PW, Morice MC, Kappetein AP, et al., for the SYNTAX Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360: 961-72.
10. Garg S, Sarno G, Girasis C, et al. A patient-level pooled analysis assessing the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention WithTaxus and Cardiac Surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. J Am Coll Cardiol Interv, 2011, 4: 645-53.
11. Gijsberts CM, Seneviratna A, Hoefer IE, et al. Inter-Ethnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. PLoS One, 2015, 10(7):
12. e0131977. Publishedonline 2015 Jul 6. doi: 10.1371/journal.pone.0131977.
13. Xu B, GОnОreux Ph, Yang Y, et al. Validation and Comparison of the Long-Term Prognostic Capability of the SYNTAX Score-II Among 1,528 Consecutive patients Who Underwent Left Main Percutaneous Coronary Intervention. J Am Coll Сardiol Intv, 2014, 7: 1128-37.
14. Palmerini T, CalabrШ P, Piscione F, et al. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention The GEPRESS Study. J Am Coll Cardiol Intv, 2014, 7: 1117-27.
15. Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614–23.
16. Komarov A, Ilyushchenko T, Dobrovolsky A et al. D-dimer, plasmin-antiplasmin complex and matrix metalloproteinase 2 as markers of cardiovascular events in patients with stable coronary disease. Abstract of the ESC Congress 2012. European Heart Journal, 2012, 33(Abstract Supplement): 305.
17. Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol, 2001, 21(4): 611-617.
18. Smith A, Patterson C, Yarnell J, et al. Which hemosta-tic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation, 2005, 112(20): 3080-3087.
19. Morange PE, Bickel C, Nicaud V, et al. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol, 2006, 26(12): 2793-2799.
20. Гуськова Е.В. Факторы, определяющие безопасность двойной антитромбоцитарной терапии после плановых чрескожных коронарных вмешательств: Автореф. дис. ... канд. мед. наук. М.: 11-й ФОРМАТ, 2016. 24 с.
Review
For citations:
Novikova E.S., Komarov A.L., Gus’kova E.V., Shakhmatova O.O., Deyev A.D., Dobrovolsky A.B., Samko A.N., Panchenko E.P. IS THE SYNTAX SCORE SUFFICIENT TO ASSESS THE RISK FOR PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS? Aterotromboz = Atherothrombosis. 2017;(1):80-93. (In Russ.) https://doi.org/10.21518/2307-1109-2017-1-80-93
Views:
1061
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 